Mesothelioma Blood Tests: 7 Biomarkers That Could Detect Cancer Years Earlier

Key Facts About Mesothelioma Blood Tests

• MESOMARK is the only FDA-approved mesothelioma blood test, cleared in 2007 for treatment monitoring — not screening or diagnosis
• MESOMARK measures soluble mesothelin-related peptides (SMRP) with 61% sensitivity and 87% specificity based on meta-analysis of 28 studies
• The SOMAmer 13-protein panel detected 88% of stage I and II mesothelioma with 92% overall accuracy
• Fibulin-3 showed 87% sensitivity and 89% specificity in one meta-analysis, potentially outperforming MESOMARK
• Hyperacetylated HMGB1 achieved 100% sensitivity and 100% specificity in a small study, but faces data integrity concerns
• MicroRNA markers showed 0% sensitivity for detecting mesothelioma in prediagnostic blood samples
• Kidney disease, other cancers, and inflammatory conditions cause false positive results with mesothelin-based tests
• A 10-year increase in age doubles the rate of false-positive mesothelin test results
• Biomarker combinations outperform single markers: mesothelin + fibulin-3 + HMGB1 achieved AUC of 0.99
• Mesothelin + calretinin detected tumors up to 15 months before clinical diagnosis in prediagnostic samples
• The median survival for mesothelioma is approximately 12 months from diagnosis, making early detection critical

What Is the Only FDA-Approved Mesothelioma Blood Test?

The MESOMARK assay, developed by Fujirebio Diagnostics and cleared by the FDA in January 2007, remains the only FDA-approved serum biomarker test for mesothelioma. It measures soluble mesothelin-related peptides (SMRP) — fragments of the mesothelin protein that are released from cell surfaces and correlate with tumor volume [6]. The test was approved specifically to aid in monitoring patients already diagnosed with mesothelioma, not as a primary diagnostic or screening tool [7].

A meta-analysis of 28 serum SMRP studies [3] found pooled sensitivity of 61% and specificity of 87%, with an area under the curve (AUC) of 0.806. Sensitivity varies significantly by histological subtype — the test performs best for epithelioid mesothelioma and may return normal levels even in patients with sarcomatoid disease.

"The MESOMARK test is a valuable monitoring tool for patients we already know have mesothelioma — it helps track whether treatment is working. But families need to understand that a normal MESOMARK result does not rule out mesothelioma, especially in early stages. That's why we always connect patients with specialists who use the full diagnostic toolkit."

— Anna Jackson, Director of Patient Support, Danziger & De Llano

MESOMARK is available through reference laboratories such as ARUP Laboratories. The test has an analytical sensitivity of 0.3 nM, meaning it can detect very small amounts of SMRP in blood. However, elevated levels can also occur in patients with kidney disease, pancreatic cancer, ovarian cancer, and certain inflammatory conditions — all of which must be considered when interpreting results.

How Does the SOMAmer 13-Protein Panel Detect Early-Stage Mesothelioma?

The most significant advancement in mesothelioma blood testing is the SOMAmer (Slow Off-rate Modified Aptamer) proteomic panel, developed by SomaLogic using their SOMAscan platform [4]. Unlike single-marker tests, this panel simultaneously measures 13 proteins using aptamer technology that can detect over 1,000 proteins in a single unfractionated blood sample.

In multicenter studies using serum from 117 mesothelioma patients and 142 asbestos-exposed controls, the 13-protein classifier achieved remarkable accuracy across multiple validation stages:

Validation Stage	AUC	Key Finding
Training set	0.99	Near-perfect discrimination
Independent blinded verification	0.98	Maintained accuracy in new samples
Blinded validation	0.95	Robust performance across centers
Combined accuracy	—	92% overall, 88% of stage I/II disease

The combined sensitivity and specificity both exceeded 90% (sensitivity 93.2%, specificity 90.8%). Critically, the panel's 13 classifier proteins had not previously been associated with mesothelioma. Their functions involve regulation of proliferation and inflammation — biological pathways central to how asbestos causes cancer. This multiplex approach far outperformed single-marker mesothelin testing (AUC 0.82, sensitivity 66%, specificity 88%) in the same patient populations [4].

"Detecting 88% of stage I and stage II disease is what makes the SOMAmer panel so important. With fewer than 5% of patients as of 2026 diagnosed at stage I, a validated screening test that catches early disease could fundamentally change survival outcomes. The gap between where we are and where this technology could take us is the reason early detection research matters so urgently."

— Anna Jackson, Director of Patient Support, Danziger & De Llano

The SOMAmer panel remains investigational and requires specialized proteomic equipment. The DIAPHRAGM prospective multicenter study was designed to validate it in a clinically relevant setting — a necessary step before it could enter routine clinical practice.

Which Other Biomarkers Show Promise for Mesothelioma Detection?

Fibulin-3

Fibulin-3 was first proposed as a mesothelioma biomarker in a landmark 2012 study published in the New England Journal of Medicine. A subsequent systematic review and meta-analysis [5] validated the finding across multiple cohorts. The initial study reported 96.7% sensitivity and 95.5% specificity, but subsequent validation produced variable results. A meta-analysis of 7 studies [1] found pooled sensitivity of 62% and specificity of 82%. A separate meta-analysis reported higher figures — 87% sensitivity and 89% specificity with AUC of 0.94 — though acknowledged substantial heterogeneity between studies.

Fibulin-3 may offer advantages over MESOMARK: meta-analytic comparisons suggest higher sensitivity (0.87 vs. 0.61) with comparable specificity. Serum-based assays showed superior diagnostic accuracy compared to plasma-based assays.

Osteopontin (OPN)

Osteopontin is a glycoprotein linked to mesothelioma since 2005. Meta-analysis of 10 studies [6] established pooled sensitivity of 57% and specificity of 81%. Patients with high serum osteopontin (>350 ng/mL) had significantly shorter survival — median 5 months versus 15 months for low levels. However, OPN is elevated in multiple other cancers (colon, lung, breast, prostate), limiting its specificity for mesothelioma.

HMGB1 (High-Mobility Group Box 1)

HMGB1 plays a central role in asbestos carcinogenesis. When asbestos fibers lodge in the pleura, mesothelial cells undergo programmed necrosis and release HMGB1, triggering chronic inflammation. A 2016 study in Clinical Cancer Research [7] reported that hyperacetylated HMGB1 discriminated mesothelioma patients from asbestos-exposed individuals with 100% sensitivity and 100% specificity. However, an expression of concern was published in 2020 regarding data integrity from one co-author, and the small sample size (22 mesothelioma patients) raises overfitting risk. Independent large-scale validation has not been completed.

MicroRNA panels

MicroRNAs are small non-coding RNAs stable in blood. Several miRNAs have been linked to mesothelioma, including miR-103a-3p (83% sensitivity, 71% specificity). A 6-miRNA signature predicted long survival with 92.3% accuracy after surgery. However, a study using prediagnostic blood samples found that miRNA markers showed 0% sensitivity at detecting mesothelioma before clinical diagnosis — suggesting they detect established disease only, not early-stage cancer.

Why Do Single Blood Tests Fail to Reliably Detect Mesothelioma?

A systematic review [1] concluded that "no serum or pleural fluid biomarker was identified that could be recommended as of 2026 for routine clinical practice." Several factors explain why:

False positive causes are pervasive. Kidney disease elevates both mesothelin and MPF levels independent of cancer. Other cancers — pancreatic, ovarian, lung — overexpress mesothelin. Inflammatory conditions including hypertension and bronchitis affect mesothelin concentrations. Age alone is a major confounder: a 10-year increase in age results in approximately 2-fold more false-positive mesothelin tests.

Histological subtype variation. SMRP performs best for epithelioid mesothelioma but may remain low in sarcomatoid disease — the subtype with the worst prognosis and greatest need for early detection.

Sample handling inconsistency. Different assay platforms yield different results on identical samples. Two MPF ELISA kits yielded sensitivity of 29% and 52% at 95% specificity on matching blood samples. Until collection and storage protocols are standardized, reproducibility will remain a barrier.

"Understanding the limitations of current blood tests is part of being a well-informed patient. A single normal blood result doesn't mean you're clear, and a single elevated result doesn't confirm mesothelioma. The best approach combines multiple tests with imaging and clinical evaluation — and never delays legal action while waiting for additional test results."

— Anna Jackson, Director of Patient Support, Danziger & De Llano

What Does the Future of Mesothelioma Blood Testing Look Like?

The strongest evidence points toward biomarker panels rather than individual markers as the path to reliable early detection. Combining fibulin-3 and HMGB1 achieved AUC of 0.987 for distinguishing mesothelioma from other pleural effusions (95.45% sensitivity, 92.11% specificity). A three-protein panel of mesothelin, fibulin-3, and HMGB1 achieved AUC of 0.99 with 96% sensitivity and 93% specificity.

The combination of mesothelin and calretinin represents a particular breakthrough: this pair detected tumors in prediagnostic blood samples [2] up to 15 months before clinical diagnosis with 46% sensitivity at 98% specificity. While 46% sensitivity is too low for population screening, it demonstrates that protein biomarkers can identify mesothelioma before symptoms emerge — a capability that microRNA markers entirely lack.

Biomarker	FDA Status	Clinical Use	Key Limitation
MESOMARK (SMRP)	FDA-approved	Treatment monitoring	Low sensitivity (61%); not for screening
Fibulin-3	Investigational	Research protocols	Variable results across studies
Osteopontin	Investigational	Research only	Elevated in multiple cancer types
SOMAmer panel	Investigational	Research only	Requires specialized equipment
HMGB1	Investigational	Research only	Data integrity concerns; small studies
MicroRNA panels	Investigational	Research only	Cannot detect prediagnostic disease
Calretinin	Investigational	Research only	Best in combination, not standalone

The combination of several biomarkers from different molecular classes — proteins, miRNAs, methylated DNA — represents the most promising path toward reliable early detection in high-risk populations. For patients with documented asbestos exposure history, discussing available monitoring options with a physician remains essential while the science advances.

What Should Mesothelioma Patients and Families Know About These Tests?

For patients already diagnosed with mesothelioma, the MESOMARK test can help track treatment response — falling SMRP levels may indicate that therapy is working. Rising levels may signal disease progression. Ask your oncologist whether MESOMARK monitoring is appropriate for your treatment plan.

For individuals with asbestos exposure history who have not been diagnosed, blood biomarkers should not replace regular medical surveillance. Imaging studies such as chest CT scans remain the primary screening tool, and any persistent respiratory symptoms should prompt immediate medical evaluation.

Regardless of diagnostic stage, time is a critical factor for both medical treatment and legal options. Mesothelioma has a median survival of approximately 12 months from diagnosis, and statutes of limitations for filing claims vary by state. An early consultation with an experienced attorney ensures that the legal process starts promptly while medical decisions remain the priority. Take our free case assessment to understand your options.

Frequently Asked Questions

Is there a blood test for mesothelioma?

Yes. The MESOMARK assay is the only FDA-approved blood test for mesothelioma, cleared in 2007 for monitoring diagnosed patients. It measures soluble mesothelin-related peptides (SMRP). Several other blood biomarkers are under investigation, including the SOMAmer 13-protein panel, fibulin-3, osteopontin, and HMGB1, but none have received FDA approval for clinical use.

How accurate is the MESOMARK blood test for mesothelioma?

MESOMARK has pooled sensitivity of approximately 61% and specificity of 87% based on a meta-analysis of 28 studies. It correctly identifies about 61% of mesothelioma cases while correctly ruling out 87% of non-mesothelioma cases. Sensitivity varies by subtype — highest for epithelioid, lowest for sarcomatoid mesothelioma.

What is the SOMAmer mesothelioma blood test?

The SOMAmer panel is a 13-protein investigational blood test that achieved 92% overall accuracy and detected 88% of stage I and II mesothelioma in clinical studies. It uses aptamer technology to measure multiple proteins simultaneously, significantly outperforming single-marker tests. The DIAPHRAGM prospective study was designed to validate it for clinical use.

Can a blood test detect mesothelioma before symptoms appear?

Current capability is limited. MicroRNA markers showed 0% sensitivity in prediagnostic samples. However, the combination of mesothelin and calretinin detected tumors up to 15 months before clinical diagnosis with 46% sensitivity at 98% specificity. The SOMAmer panel detected 88% of early-stage disease in diagnosed patients, but prediagnostic validation data is still needed.

What causes false positive mesothelioma blood test results?

Kidney disease is a major cause of false positives because it reduces clearance of mesothelin. Other cancers (pancreatic, ovarian, lung) also elevate mesothelin levels. Age is a significant confounder — a 10-year increase results in approximately 2-fold more false positives. Inflammatory conditions including hypertension and bronchitis can also affect results.

Should asbestos-exposed workers get regular mesothelioma blood tests?

No population-level screening program using blood biomarkers is as of 2026 recommended. Individuals with documented asbestos exposure should discuss monitoring with their physician, but imaging (chest CT) remains the primary surveillance tool. Biomarker panel testing may become part of screening protocols as research advances, particularly the SOMAmer panel and mesothelin-calretinin combination.

What Sources Were Used in This Article?

Peer-Reviewed Literature

1. Cui A, et al. "Diagnostic and prognostic biomarkers for malignant mesothelioma: an update." Translational Lung Cancer Research. 2017. PMC5504120.
2. Johnen G, et al. "Calretinin as a blood-based biomarker for mesothelioma." BMC Cancer. 2017. PMC5450182.
3. Hu ZD, et al. "Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma." BMJ Open. 2014.
4. Ostroff RM, et al. "Early detection of malignant pleural mesothelioma in asbestos-exposed individuals." PLoS ONE. 2012. PMC3463527.
5. Pass HI, et al. "Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma." New England Journal of Medicine. 2012. Validated by: "Diagnostic value of fibulin-3 for malignant pleural mesothelioma." Oncotarget. 2016. PMC5356703.
6. Huang J, et al. "Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis." Int J Clin Exp Med. 2014. PMC4073746.
7. Napolitano A, et al. "HMGB1 and its hyperacetylated isoform as serum biomarkers." Clinical Cancer Research. 2016. PMC4867109.
8. "Circulating biomarkers and targeted therapy in pleural mesothelioma." PMC12691059. 2025.

Government and Institutional Sources

• U.S. Food and Drug Administration. MESOMARK assay patient information.
• Fujirebio Diagnostics. FDA approval announcement for MESOMARK assay. 2007.
• National Cancer Institute. "Malignant Mesothelioma Treatment."
• Agency for Toxic Substances and Disease Registry. "Asbestos Health Effects."